GlassScriptPhysician profile
Carolee Rose Boyd
NPI 1376571679
$6,067.13
in general payments reported to CMS, 2019-2025
18 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $207 · 2021: $570 · 2022: $332 · 2023: $634 · 2024: $838 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,276.18 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $1,066.00 | 2022-2025 | Infuse, Miebo, Infuse Multifocal |
| Alcon Vision LLC | $1,022.12 | 2019-2025 | Precision7, Precision 1, Total30 |
| Allergan, INC. | $249.46 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $212.63 | 2019-2020 | |
| Abbvie INC. | $190.61 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Glaukos Corporation | $181.95 | 2023 | |
| Sun Pharmaceutical Industries INC. | $165.58 | 2019 | |
| Amgen INC. | $121.13 | 2024 | |
| Biotissue Holdings INC. | $100.46 | 2023-2025 | |
| Astellas Pharma US INC | $97.20 | 2024 | Izervay |
| Spark Therapeutics, INC. | $91.82 | 2019 | |
| Visioneering Technologies, INC. | $75.12 | 2019-2022 | |
| Lkc Technologies, INC. | $66.77 | 2022 | |
| Sight Sciences, INC. | $65.42 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $46.84 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $19.37 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $18.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolee Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.